Anuh Pharma (BOM:506260) EBIT: ₹547 Mil (TTM As of Mar. 2026)


BOM:506260 Anuh Pharma Ltd BOM:506260
81 GF Score
Price ₹81.49
GF Value ₹105.32
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Anuh Pharma EBIT?

Anuh Pharma BOM:506260 +1.88% 81 EBIT is ₹547 Mil as of Mar. 2026. GuruFocus rates BOM:506260 with a GF Score™ of 81/100 and a GF Value™ of ₹105.32 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Anuh Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹156 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹547 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anuh Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 16.22%. Anuh Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anuh Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.17%.


Anuh Pharma  (BOM:506260) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anuh Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=675.196 * ( 1 - 24.73% )/( (0 + 3132.922)/ 1 )
=508.2200292/3132.922
=16.22 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5573.679 - 1899.734 - ( 541.023 - max(0, 2030.033 - 4513.156+541.023))
=3132.922

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Anuh Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=625.012/( ( (0 + max(0, 0)) + (560.918 + max(1934.419, 0)) )/ 1 )
=625.012/( ( 0 + 2495.337 )/ 1 )
=625.012/2495.337
=25.05 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2386.328 + 1477.55 + 99.991) - (1899.734 + 0 + 129.716)
=1934.419

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anuh Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=546.937/7626.814
=7.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anuh Pharma EBIT Related Terms


Anuh Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Anuh Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anuh Pharma EBIT Chart

Anuh Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 400.83 476.89 786.63 616.25 546.94

Anuh Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 173.13 111.64 99.96 179.08 156.25

BOM:506260 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anuh Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anuh Pharma's EV-to-EBIT falls into.


BOM:506260
81GF Score
Anuh Pharma Ltd BOM:506260
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anuh Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹547 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹547 Mil mean?
Anuh Pharma (BOM:506260) has a EBIT of ₹547 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anuh Pharma.
Is Anuh Pharma's EBIT too high?
Anuh Pharma's current EBIT is ₹547 Mil. Overall, Anuh Pharma has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's EBIT compare to ZTS and UTHR?
Anuh Pharma's EBIT of ₹547 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anuh Pharma. Anuh Pharma's current EBIT is ₹547 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.32, compared to a current price of ₹81.49 — trading 22.6% below its estimated fair value. The current EBIT is ₹547 Mil. Anuh Pharma's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current EBIT is ₹547 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anuh Pharma (BOM:506260) Overvalued in 2026?

Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued. The current stock price of ₹81.49 is trading 22.6% below its estimated GF Value™ of ₹105.32. GuruFocus considers Anuh Pharma to be Modestly Undervalued.

Key valuation signals for BOM:506260:

  • EBIT: ₹547 Mil
  • GF Value™: ₹105.32 vs. price of ₹81.49 (22.6% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anuh Pharma Business Description

Other Exchanges ANUHPHR:India
Address Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
81GF Score

Get the complete analysis for BOM:506260

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹81.49
Price
₹105.32
GF Value